ChemicalBook > CAS DataBase List > Ongericimab
Ongericimab
- Product Name
- Ongericimab
- CAS No.
- 2145096-91-7
- Chemical Name
- Ongericimab
- Synonyms
- Ongericimab;Ongericimab (anti-PCSK9);Research Grade Ongericimab;Research Grade Ongericimab (DHJ24008)
- CBNumber
- CB510616959
- Formula Weight
- 0
- MOL File
- Mol file
More
Less
Ongericimab Chemical Properties,Usage,Production
Uses
Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia[1].
References
[1] Min C, et, al. Application of PCSK9 inhibitor in preparation of product for promoting hair growth. CN113876955.
Ongericimab Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
Ongericimab Suppliers
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 71826
- Advantage
- 60
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ:422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 6762
- Advantage
- 58
- Tel
- 0731-13823398 15111215862
- 313359644@qq.com
- Country
- China
- ProdList
- 4161
- Advantage
- 58
- Tel
- 0573-83568680 18057391398
- 3956524501@qq.com
- Country
- China
- ProdList
- 1442
- Advantage
- 58
- Tel
- 027-87008169 17762441161
- info@atagenix.com
- Country
- China
- ProdList
- 10001
- Advantage
- 58
- Tel
- 33175446423
- support@antibodysystem.com
- Country
- China
- ProdList
- 6739
- Advantage
- 58
2145096-91-7, OngericimabRelated Search:
Adintrevimab
Lilotomab
Licaminlimab
Imciromab
Bafisontamab
Risankizumab
Prolgolimab
Fidasimtamab
clenoliximab
Praluzatamab